LifeStance Health Group/$LFST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LifeStance Health Group
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
- Ticker
- $LFST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 8,542
- Headquarters
- Scottsdale, United States
- Website
- lifestance.com
LFST Metrics
BasicAdvanced
$5.1B
104.01
$0.13
1.22
-
Price and volume
Market cap
$5.1B
Beta
1.22
52-week high
$13.76
52-week low
$4.77
Average daily volume
3.5M
Financial strength
Current ratio
1.376
Quick ratio
1.226
Long term debt to equity
0.28
Total debt to equity
0.324
Interest coverage (TTM)
7.95%
Profitability
EBITDA (TTM)
135.005
Gross margin (TTM)
33.56%
Net profit margin (TTM)
3.19%
Operating margin (TTM)
5.08%
Effective tax rate (TTM)
24.47%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
2.32%
Return on equity (TTM)
3.43%
Valuation
Price to earnings (TTM)
104.006
Price to revenue (TTM)
3.265
Price to book
3.47
Price to tangible book (TTM)
-24,057.45
Price to free cash flow (TTM)
29.758
Free cash flow yield (TTM)
3.36%
Free cash flow per share (TTM)
0.45
Growth
Revenue change (TTM)
20.38%
Earnings per share change (TTM)
-405.30%
3-year revenue growth (CAGR)
18.22%
3-year earnings per share growth (CAGR)
-34.38%
What the Analysts think about LFST
Analyst ratings (Buy, Hold, Sell) for LifeStance Health Group stock.
Analyst projections of the future price of LifeStance Health Group stock.
Bulls say / Bears say
Second-quarter revenue rose 26% year on year, with visits up 19% and the clinician base up 11%. Management raised its full-year 2026 revenue outlook, showing that growth is running ahead of its earlier expectations. (LifeStance Health)
Profitability is improving alongside growth: second-quarter net income was $23.6 million versus a year-earlier loss, while adjusted EBITDA nearly doubled to $66 million. The company also lifted its full-year adjusted EBITDA outlook. (LifeStance Health)
LifeStance has room to expand beyond its current footprint: it plans to enter more major US markets in 2027 through targeted acquisitions and new centres. That could extend its reach in a fragmented market and support future growth. (Behavioral Health Business)
Revenue is highly reliant on commercial insurers: they accounted for 88% of second-quarter revenue, and two payers each contributed at least 14%. If major insurers push down rates or restrict coverage, earnings could be pressured. (SEC)
Growth depends on recruiting and retaining clinicians, but competition for therapists is intensifying as providers seek to hire from the same workforce. That could make it harder or more costly for LifeStance to add the clinicians needed to sustain expansion. (Behavioral Health Business)
The strong second-quarter cash flow may not be a reliable run rate: management said it benefited from payroll timing and flagged about $60 million of related payments in the next quarter. Planned investment and $60–70 million of expected stock-based compensation also weigh on the quality of reported profitability. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
LFST Financial Performance
Revenues and expenses
LFST Earnings Performance
Company profitability
Upcoming events
No upcoming events
LFST News
AllArticlesVideos
Funds containing LFST
AllUSDEURGBP
Fund name | Fund size | $LFST weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.29% |
iShares Ageing Population£AGES | $953M | 0.29% |
iShares Ageing Population€AGED | $903M | 0.29% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.21% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.